A Palumbo

Summary

Publications

  1. ncbi Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Italy
    Clin Lymphoma Myeloma 6:475-7. 2006
  2. doi Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010
  3. pmc Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy
    Barbara Lupo
    Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, 10126 Torino, Italy
    Adv Hematol 2012:906247. 2012
  4. ncbi Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy Electronic address
    Lancet Oncol 15:333-42. 2014
  5. doi Role of consolidation/maintenance therapy in multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy Electronic address
    Clin Lymphoma Myeloma Leuk 13:S349-54. 2013
  6. doi The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma
    Chiara Pautasso
    University of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy 39 01 1663 5814 39 01 1696 3737
    Expert Opin Drug Metab Toxicol 9:1371-9. 2013
  7. pmc Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, Rome, Italy
    J Transl Med 10:247. 2012
  8. pmc Diagnosis and therapy of multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Korean J Intern Med 28:263-73. 2013
  9. pmc Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
    Sara Bringhen
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Haematologica 98:980-7. 2013
  10. doi Management of older adults with multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
    Blood Rev 27:133-42. 2013

Detail Information

Publications94

  1. ncbi Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Italy
    Clin Lymphoma Myeloma 6:475-7. 2006
    ..Bortezomib and thalidomide have shown synergy with melphalan and dexamethasone. We used this 4-drug combination as conditioning before autologous hematopoietic cell infusions...
  2. doi Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    Marco Ladetto
    Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:2077-84. 2010
    ..Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs...
  3. pmc Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy
    Barbara Lupo
    Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, 10126 Torino, Italy
    Adv Hematol 2012:906247. 2012
    ..Therefore, here, we will also provide a description of the main adverse events associated with lenalidomide and its combination...
  4. ncbi Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy Electronic address
    Lancet Oncol 15:333-42. 2014
    ..Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure...
  5. doi Role of consolidation/maintenance therapy in multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy Electronic address
    Clin Lymphoma Myeloma Leuk 13:S349-54. 2013
    ..Prolonged exposure to a drug might in fact increase toxicity, and prompt management of adverse events is necessary. ..
  6. doi The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma
    Chiara Pautasso
    University of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy 39 01 1663 5814 39 01 1696 3737
    Expert Opin Drug Metab Toxicol 9:1371-9. 2013
    ..This led to the continuous development of novel agents. Carfilzomib is a second-generation proteasome inhibitor, demonstrating promising results in relapsed/refractory (RR) and newly diagnosed (ND) MM patients...
  7. pmc Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
    Giuseppina Bonanno
    Department of Gynecology, Catholic University Med School, Rome, Italy
    J Transl Med 10:247. 2012
    ..It is presently unknown whether MM cells express IDO1 and whether IDO1 activity correlates with immune system impairment...
  8. pmc Diagnosis and therapy of multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Korean J Intern Med 28:263-73. 2013
    ..Elderly patients are usually not eligible for transplantation, and gentler approaches with new drugs combinations are used for their treatment...
  9. pmc Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
    Sara Bringhen
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
    Haematologica 98:980-7. 2013
    ..A detailed geriatric assessment, organ evaluation and less intense individualized approaches are suggested in elderly unfit subjects...
  10. doi Management of older adults with multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
    Blood Rev 27:133-42. 2013
    ..In this setting, less toxic regimens and appropriate dose reductions should be adopted. Here we provide an overview of novel agent-based treatment strategies for elderly patients with multiple myeloma...
  11. doi Have drug combinations supplanted stem cell transplantation in myeloma?
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
    Hematology Am Soc Hematol Educ Program 2012:335-41. 2012
    ..This article provides an overview of recent and ongoing clinical trials and aims to define the role of ASCT in the era of novel agents...
  12. doi Have drug combinations supplanted stem cell transplantation in myeloma?
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
    Blood 120:4692-8. 2012
    ..This article provides an overview of recent and ongoing clinical trials and aims to define the role of ASCT in the era of novel agents...
  13. ncbi Part II: role of maintenance therapy in transplant-ineligible patients
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
    J Natl Compr Canc Netw 11:43-9. 2013
    ..This article provides an overview of the main trials including consolidation/maintenance therapy after induction for transplant-ineligible patients. Recommendations on how to manage treatment-related toxicities are also provided...
  14. pmc Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, AOU S Giovanni Battista, Torino, Italy
    Haematologica 98:87-94. 2013
    ..Serious non-hematologic toxicities, older age, poor Performance Status, and high creatinine levels negatively affected survival...
  15. doi Sustained disease control in transplant-ineligible patients: the role of continuous therapy
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero Universitaria, San Giovanni Battista di Torino, Turin, Italy
    Leuk Res 36:S19-26. 2012
    ....
  16. doi Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero Universitaria, S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    N Engl J Med 366:1759-69. 2012
    ....
  17. doi How to manage neutropenia in multiple myeloma
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Turin, Italy
    Clin Lymphoma Myeloma Leuk 12:5-11. 2012
    ..If ANC restores to > 1000 cells/mL, therapy can be resumed with no dose modifications. In case of persistence of severe neutropenia, treatment should be delayed until ANC reaches > 1000 cells/mL, and dose reductions are necessary...
  18. doi Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Ann Oncol 19:1160-5. 2008
    ..Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and low-dose dexamethasone (PAd) in the treatment of relapsed/refractory myeloma...
  19. doi Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Antonio Palumbo
    Myeloma Unit, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Italy
    Blood Rev 25:181-91. 2011
    ....
  20. doi Thalidomide for treatment of multiple myeloma: 10 years later
    Antonio Palumbo
    Division of Hematology, University of Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 111:3968-77. 2008
    ..Future studies will define the most effective or the best sequence of combinations which could improve life expectancy...
  21. doi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    ....
  22. doi Lenalidomide: a new therapy for multiple myeloma
    Antonio Palumbo
    Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Cancer Treat Rev 34:283-91. 2008
    ....
  23. doi Treatment of newly diagnosed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, Turin, Italy
    Curr Hematol Malig Rep 3:107-14. 2008
    ..The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM...
  24. doi Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, AOU S Giovanni Battista, Turin, Italy
    Leukemia 24:1037-42. 2010
    ..In conclusion, RMPT is an active salvage therapy with good efficacy and manageable side effects. This study represents the basis for larger phase III randomized trials...
  25. pmc Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
    Antonio Palumbo
    Divisione, di Ematologia Dell Università di Torino, Azienda Ospedaliera San, Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Haematologica 95:1144-9. 2010
    ....
  26. doi Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 28:800-7. 2010
    ..CONCLUSION Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance, is an effective regimen...
  27. doi Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Blood 115:1873-9. 2010
    ..We conclude that MEL200 leads to longer remission duration and should be considered the standard conditioning regimen for autologous transplantation. This study was registered at www.clinicaltrials.gov as #NCT00950768...
  28. doi International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Torino 10126, Italy
    Leukemia 23:1716-30. 2009
    ..These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM...
  29. doi Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Clin Lymphoma Myeloma 9:145-50. 2009
    ..This updated analysis reassessed the kinetics of neutropenia and thrombocytopenia as well as the safety and efficacy of MPR...
  30. doi Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
    A Palumbo
    University of Torino, Turin, Italy
    Ann Hematol 89:803-11. 2010
    ....
  31. ncbi Treatment of newly diagnosed myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
    Leukemia 23:449-56. 2009
    ..If these data will be confirmed, a cytogenetically risk-adapted strategy might become the most appropriate strategy...
  32. doi Update on recent developments for patients with newly diagnosed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Ann N Y Acad Sci 1138:19-21. 2008
    ..Combination regimens containing bortezomib or thalidomide can achieve response rates, especially complete response rates, which are superior to those seen with standard MP alone, and offer new possibilities for this patient population...
  33. doi Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
    Blood Rev 23:87-93. 2009
    ..The recommendations presented here will aid the safe administration of lenalidomide, and avoid unnecessary dose reduction and discontinuation, thus assuring the best efficacy of treatment...
  34. doi Multiple myeloma: chemotherapy or transplantation in the era of new drugs
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Eur J Haematol 84:379-90. 2010
    ..Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs...
  35. ncbi Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
    A Palumbo
    Division of Hematology, University of Turin, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leukemia 22:414-23. 2008
    ..Further investigation is needed to define the best VTE prophylaxis...
  36. doi Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
    Antonio Palumbo
    Division of Hematology, University of Torino, Azinda Ospedaliero Universitaria S Giovanni Battista, Torino, Italy
    Blood 118:4519-29. 2011
    ..Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes...
  37. ncbi Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
    Blood 109:2767-72. 2007
    ..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low...
  38. ncbi Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
    Lancet 367:825-31. 2006
    ..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years...
  39. doi The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Expert Opin Drug Saf 11:107-20. 2012
    ..Long-term continuous treatment with lenalidomide beyond first response may be important to optimize responses and delay relapse...
  40. ncbi Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
    Antonio Palumbo
    Division of Hematology, University of Torino, San Giovanni Battista Hospital, Turin, Italy
    Cancer 110:824-9. 2007
    ..Baseline parameters that may be predictive of outcome after thalidomide treatment have been investigated to identify which myeloma patient subgroups will most benefit from this drug...
  41. doi Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy
    Clin Cancer Res 17:1253-63. 2011
    ..Physicians now have a wider variety of treatment options to tailor the most appropriate and efficacious treatment according to their patients' characteristics...
  42. ncbi Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
    ..We assessed dosing, efficacy, and safety of melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed elderly myeloma patients...
  43. ncbi A new standard of care for elderly patients with myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino 10126, Italy
    Lancet 370:1191-2. 2007
  44. doi Dose reduction in spiral CT coronary angiography with dual-source equipment. Part I. A phantom study applying different prospective tube current modulation algorithms
    C Martini
    Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
    Radiol Med 114:1037-52. 2009
    ..The authors sought to compare different algorithms for dose reduction in retrospectively echocardiographically (ECG)-gated dual-source computed tomography (CT) coronary angiography (DSCT-CA) in a phantom model...
  45. doi Prognostic value of Morise clinical score, calcium score and computed tomography coronary angiography in patients with suspected or known coronary artery disease
    E Maffei
    Department of Radiology and Cardiology, Azienda Ospedaliero Universitaria, Parma, Italy
    Radiol Med 116:1188-202. 2011
    ..Our aim was to determine the prognostic value of computed tomography coronary angiography (CTCA), coronary artery calcium scoring (CACS) and Morise clinical score in patients with known or suspected coronary artery disease (CAD)...
  46. ncbi Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leukemia 18:133-8. 2004
    ..The intensified nonmyeloablative MEL100 regimen is an effective first-line treatment...
  47. doi Functional parameters of the left ventricle: comparison of cardiac MRI and cardiac CT in a large population
    A Palumbo
    Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
    Radiol Med 115:702-13. 2010
    ..The authors sought to compare magnetic resonance imaging (MRI) and computed tomography (CT) for assessing left ventricular (LV) function parameters in a large patient population...
  48. ncbi Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia, l Università di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
    Eur J Haematol 76:273-7. 2006
    ..To address this issue, feasibility and efficacy of a three drug combination consisting of intravenous (i.v.) melphalan, thalidomide and prednisone [M(i.v.)PT] was evaluated in advanced myeloma patients...
  49. ncbi Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
    A Palumbo
    , Azienda Ospedaliera S. Giovanni Battista, Torino, Italy
    Haematologica 86:399-403. 2001
    ..A significant proportion of patients benefit from this treatment as a salvage therapy postponing the delivery of chemotherapy...
  50. ncbi Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
    Haematologica 87:846-50. 2002
    ....
  51. ncbi Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Eur J Haematol 75:391-5. 2005
    ..The aim of the study was to define the best treatment option for patients relapsing after AT...
  52. ncbi The future role of thalidomide in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia, Ospedale Molinette, Torino, Italy
    Acta Haematol 114:18-22. 2005
    ..The workshop acknowledged the problems associated with designing a phase III study, and it is clear that many areas need to be addressed in the use of thalidomide for the treatment of multiple myeloma...
  53. ncbi Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
    Cancer 104:1428-33. 2005
    ..No data are available on the association of thalidomide with oral melphalan and prednisone, still considered the standard treatment for elderly patients...
  54. doi Multiple myeloma: management of adverse events
    F Gay
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Via Genova 3, 10126, Torino, Italy
    Med Oncol 27:646-53. 2010
    ..This chapter will focus on frequency and management of main adverse events in newly diagnosed and relapsed myeloma patients and will provide guidelines for dose reductions and supportive therapy...
  55. ncbi Investigational treatments for multiple myeloma
    Sara Bringhen
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    Expert Opin Investig Drugs 15:1565-82. 2006
    ..Their mechanisms of action, the available knowledge on their efficacy, safety and possible future clinical application are reviewed...
  56. doi Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    ..34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934...
  57. doi Computed tomography coronary angiography in asymptomatic patients
    E Maffei
    Department of Radiology and Cardiology, c o Piastra Tecnica, Piano 0, Azienda Ospedaliero Universitaria, Via Gramsci 14, 43100, Parma, Italy
    Radiol Med 116:1161-73. 2011
    ..This study assessed the accuracy of computed tomography coronary angiography (CT-CA) for detecting significant coronary artery disease (CAD; ≥50% lumen reduction) in intermediate/high-risk asymptomatic patients...
  58. doi Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
    T Guglielmelli
    Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Orbassano, Turin, Italy
    Eur J Cancer 47:814-8. 2011
    ..The aim of this retrospective analysis is to evaluate the impact of thalidomide therapy on lenalidomide response and outcome in relapse or refractory multiple myeloma patients...
  59. ncbi Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation
    Kenneth C Anderson
    University of Torino, Torino, Italy
    Oncology (Williston Park) 19:447-50. 2005
    ..multiplemyeloma.org and are published on a regular basis in ONCOLOGY. For more information about the interactive series, see the MMRF ad on page 552...
  60. pmc Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
    Benedetto Bruno
    Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy
    Blood 113:3375-82. 2009
    ..http://ClinicalTrials.gov; NCT-00702247.)...
  61. doi Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
    F Cavallo
    Myeloma Unit, Division of Hematology, University of Torino, AOU S Giovanni Battista, Torino, Italy
    Leukemia 25:1627-31. 2011
    ..In conclusion, we confirm that a short induction with lenalidomide allowed sufficient stem cells collection to perform autologous transplantation in 91% of newly diagnosed patients...
  62. ncbi Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells
    P Corradini
    Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni Battista Divisione Universitaria di Ematologia, Torino, Italy
    J Clin Oncol 17:208-15. 1999
    ..To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation of hematopoietic cells...
  63. ncbi Defibrotide: a review on clinical use and future development
    A Larocca
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Torino, Italy
    Expert Opin Biol Ther 8:1201-12. 2008
    ..Defibrotide is a deoxyribonucleic acid derivative that has been developed for the treatment of different vascular disorders...
  64. doi Lenalidomide and its role in the management of multiple myeloma
    Patrizia Falco
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Expert Rev Anticancer Ther 8:865-74. 2008
    ..Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma...
  65. ncbi A comparison of allografting with autografting for newly diagnosed myeloma
    Benedetto Bruno
    San Giovanni Battista Hospital, University of Turin, Turin, Italy
    N Engl J Med 356:1110-20. 2007
    ..In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts...
  66. ncbi Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
    Hematol J 5:318-24. 2004
    ..The clinical outcome of patients treated with THAL-DEX was compared with that of a control group treated with conventional chemotherapy (CC)...
  67. ncbi Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Blood 104:3052-7. 2004
    ..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients...
  68. ncbi Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
    S Mariani
    Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale, Torino, Italy
    Leukemia 19:664-70. 2005
    ..Mevastatin, a specific inhibitor of hydroxy-methylglutaryl-CoA reductase, completely abrogated this antimyeloma activity...
  69. doi Impact of contrast material volume on quantitative assessment of reperfused acute myocardial infarction using delayed-enhancement 64-slice CT: experience in a porcine model
    C Martini
    Department of Radiology and Cardiology, c o Piastra Tecnica Piano 0, Azienda Ospedaliero Universitaria, Parma, Italy
    Radiol Med 115:22-35. 2010
    ..Our purpose in this study was to compare the impact of contrast material volume in delayed-enhancement computer tomography (CT) imaging for assessing acute reperfused myocardial infarction...
  70. ncbi New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma
    M Boccadoro
    Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
    Ann Oncol 13:55-8. 2002
  71. ncbi Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
    Tommaso Caravita
    Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy
    Nat Clin Pract Oncol 3:374-87. 2006
    ..This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors...
  72. ncbi CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
    Roberto Piva
    Center for Experimental Research and Medical Studies CeRMS and Department of Biomedical Sciences and Human Oncology, University of Torino, Via Santena 5, Turin, Italy
    Blood 111:2765-75. 2008
    ....
  73. ncbi New drugs for treatment of multiple myeloma
    Benedetto Bruno
    Division of Haematology, University of Turin, Department of Medicine and Experimental Oncology, Laboratory of Haematology and Oncology, Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Italy
    Lancet Oncol 5:430-42. 2004
    ..Here, we discuss the mechanisms of action of these new rational drugs and the preliminary clinical outcomes of a new treatment regimen for MM...
  74. ncbi Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
    M Ladetto
    Division of Hematology, A O Azienda Ospedaliera Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
    Leukemia 28:1299-307. 2014
    ..We conclude that NGS is an effective tool for MRD monitoring in ALL, MCL and MM. Prospective comparative analysis of unselected cases is required to validate the clinical impact of NGS-based MRD assessment. ..
  75. ncbi Melphalan and its role in the management of patients with multiple myeloma
    Patrizia Falco
    Azienda Ospedaliera San Giovanni Battista, Divisione di Ematologia dell Universita di Torino, Torino, Italy
    Expert Rev Anticancer Ther 7:945-57. 2007
    ....
  76. ncbi Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
    Marco Ladetto
    Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Blood 105:4784-91. 2005
    ..Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology...
  77. ncbi Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests
    Marco Ladetto
    Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Exp Hematol 30:529-36. 2002
    ..In this study, we used a validated real-time polymerase chain reaction (PCR) strategy to evaluate LTC of BM and PBPC samples obtained from MM patients...
  78. ncbi The treatment of the elderly multiple myeloma patients
    Federica Cavallo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
    Leuk Lymphoma 48:469-80. 2007
    ..In this review we present the data available on the most recent trials dealing with the treatment of elderly MM patients...
  79. doi Dose reduction in spiral CT coronary angiography with dual source equipment. Part II. Dose surplus due to slope-up and slope-down of prospective tube current modulation in a phantom model
    C Martini
    Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
    Radiol Med 115:36-50. 2010
    ....
  80. doi Management of disease- and treatment-related complications in patients with multiple myeloma
    Francesca Gay
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
    Med Oncol 27:S43-52. 2010
    ..This chapter will provide an overview of frequency and management of main complications related to the disease itself and to the use of new drugs in newly diagnosed and relapsed patients with myeloma...
  81. doi Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
    Vittorio Montefusco
    Department of Hematology, Allogeneic Bone Marrow Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Leuk Lymphoma 49:2156-62. 2008
    ..The only variable significantly associated with ONJ was antibiotic prophylaxis (p = 0.012), which had a protective effect. Thus, we speculated that antibiotic prophylaxis may prevent ONJ occurrence after dental procedures...
  82. doi Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
  83. doi A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS Oncology Referral Center of Basilicata, Rionero in Vulture PZ, Italy
    Cancer 113:1588-95. 2008
    ..Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM). No data are available on the efficacy of zoledronic acid in these patients...
  84. ncbi Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma
    Patrizia Falco
    Hematol J 5:456-7. 2004
  85. ncbi Efficacy and safety of bortezomib in patients with plasma cell leukemia
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, CROB Reference Cancer Center of Basilicata, Rionero in Vulture PZ, Italy
    Cancer 109:2285-90. 2007
    ..Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of bortezomib in PCL is scanty and derives from anecdotal, single-case reports...
  86. ncbi Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide
    Pellegrino Musto
    Unit of Hematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza Hospital, S Giovanni Rotondo, Italy
    Leuk Res 30:283-5. 2006
    ....
  87. doi Thalidomide and lenalidomide: Mechanism-based potential drug combinations
    Sonia Vallet
    Division of Hematology and Oncology, Cancer Center, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 49:1238-45. 2008
    ..Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects...
  88. pmc Thromboembolic events with lenalidomide-based therapy for multiple myeloma
    Smitha Patiyil Menon
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 112:1522-8. 2008
    ..The purpose was to evaluate the incidence and risk factors of thromboembolism associated with lenalidomide therapy in newly diagnosed myeloma...
  89. doi Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  90. ncbi Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma
    Massimo Offidani
    Clinica di Ematologia Polo Ospedaliero Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy
    Eur J Haematol 78:297-302. 2007
    ..We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin...
  91. ncbi Management of newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 21:1141-56, ix-x. 2007
    ..Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments...
  92. ncbi Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study
    Antonio Palumbo
    Haematologica 90:858-60. 2005
    ..Multiple regression analysis adjusting for several covariates was used. Improved FACT-An scores in women and men were associated with hemoglobin increase up to sex-specific normal values...
  93. pmc MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
    Flavia Pichiorri
    Department of Molecular Virology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:12885-90. 2008
    ..In summary, we have described a MM miRNA signature, which includes miRNAs that modulate the expression of proteins critical to myeloma pathogenesis...
  94. doi The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008